Table 1.
Patient demographics and clinical characteristics for all patients ≤70 years of age at baseline
| Characteristics | NABTT Historical: RT +non-TMZ drug(N=217) | EORTC Phase III: RT +TMZ (N=287) | NABTT RT + TMZ: CD4 (N=49) | NABTT RT + TMZ + new agent(N=244) |
|---|---|---|---|---|
| No. of Patients (%) | No. of Patients (%) | No. of Patients (%) | No. of Patients (%) | |
| Age, years | ||||
| Median (Range) | 54 (21–70) | 56 (19–70) | 58 (29–69) | 55 (21–70) |
| 50–70 | 148 (68%) | 197 (69%) | 38 (78%) | 162 (66%) |
| Sex | ||||
| Male | 140 (65%) | 185 (64%) | 28 (57%) | 144 (59%) |
| KPS** | ||||
| 90–100 | 129 (70%) | 249 (86%) | 39 (80%) | 180(77%) |
| 60–80 | 50 (30%) | 38 (13%) | 10 (20%) | 64 (26%) |
| Extent of surgery | ||||
| Biopsy | 26 (12%) | 48 (17%) | 9 (18%) | 55 (23%) |
| Debulking | 143 (66%) | 239 (83%) | 40 (82%) | 186 (76%) |
| Other or Missing* | 48* (22%) | 3 (1%) | ||
| Weeks from diagnosis to treatment | ||||
| Median (Range) | 3.9 (1.0–9.7) | 5 (1.7–10.7) | 3.1 (2–7.7) | 4.1 (1.9–12.7) |
| MMSE score | ||||
| 27–30 | 138 (64%) | 196 (68%) | 117 (84%) | |
| ≤ 26 | 29 (13%) | 81 (28%) | 39 (16%) | |
| Missing | 50 (23%) | 10 (3%) | ||
| Corticosteroids | ||||
| Yes | 147 (68%) | 193 (67%) | 42 (86%) | 179 (73%) |
| Histological diagnosis | ||||
| Glioblastoma | 165 (98%) | 221 (92%) | 49 (100%) | 239 (98%) |